|
Mavacamten’s HFpEF Potential | Swiss Army Surgery
October 3, 2024
|
|
|
|
|
Together with
|
|
|
|
“Everyone involved has accepted that those actions taken in the moment were outside normal procedures, and should not have been necessary.”
|
|
Royal Sussex Hospital after one of its surgeons used his Swiss Army knife to open a patient’s chest during cardiac arrest.
|
|
|
|
A new HFpEF treatment might be on the horizon, after results from the EMBARK-HFpEF trial showed that BMS’ hypertrophic cardiomyopathy treatment, mavacamten (Camzyos), safely improved key HFpEF symptoms and biomarkers.
- Mavacamten is the only cardiac myosin inhibitor with FDA approval to treat obstructive HCM, and works by reducing heart muscle contraction and improving blood flow.
- That action could also help treat HFpEF, a disease with limited treatment options.
To test mavacamten’s HFpEF potential, the open-label Phase 2a EMBARK-HFpEF trial treated 30 HFpEF patients with mavacamten (avg age 76, NYHA Class II & III, LVEF ≥60%), finding notable 26-week improvements to…
- NTproBNP: −26%
- hsTnT: −13%
- hsTnI: −20%
- NYHA class: 41.7% of measured patients
These improvements regressed to baseline over the study’s eight-week washout period, indicating a true treatment effect.
Although there were no unexpected safety events, the trial did reveal LVEF concerns that are typical with cardiac myosin inhibitors. The patients had a 3.2 percentage point average LVEF reduction, and three of the patients had to interrupt mavacamten due to LVEF declines.
The authors were encouraged by the EMBARK-HFpEF trial, which might be small and open-label, but appears to show that cardiac myosin inhibitors have a positive effect on HFpEF patients, particularly those with LVEF at the high-end of normal.
- Mavacamtem’s apparent effectiveness among patients with LVEF over 60% might be notable, given that these patients are believed to see less benefits from the major neurohormonal HFpEF therapies.
The trial also adds anticipation for BMS’ slightly larger AURORA-HFpEF Phase 2a double-blinded RCT, which will further evaluate the safety, tolerability, and exposure-response of a next-generation cardiac myosin inhibitor, MYK-224, in patients with symptomatic HFpEF.
The Takeaway
Mavacamten still has a lot to prove, but these initial results show that it does address key HFpEF biomarkers and symptoms, with a similar safety profile as its widely accepted use among HCM patients.
|
|
|
FFRCT Slashes PAD + CAD Mortality
See how adding HeartFlow’s FFRCT assessments to patient workups prior to peripheral artery disease surgeries can have a massive impact on coronary artery disease outcomes, including major reductions in long term heart attack and mortality risks.
|
|
Addressing Coronary Artery Disease
Learn how the AGENT™ Drug-Coated Balloon provides a new treatment option for in-stent restenosis in the U.S. Rx Only. (Sponsored by Boston Scientific)
|
|
Forging the Future of Cardiovascular Care
Cardiology is changing, and for the better. Get a view into Lee Health Heart Institute’s medical director Richard Chazal, MD’s vision for a new era in cardiology, driven by imaging, AI and personalized medicine.
|
|
- Swiss Army Surgery: The Royal Sussex Hospital in Brighton, England is under fire after a surgeon used his Swiss Army knife to open a patient’s chest during cardiac arrest, claiming he couldn’t find a sterile scalpel. While the patient survived, colleagues called the surgeon’s actions “questionable” and were “very surprised” that he couldn’t locate proper tools, noting that he typically used the knife to cut his lunch. Documents also revealed that the surgeon recently performed three low-risk surgeries where all patients died.
- Atherosclerosis Imaging Predicts Mortality: Researchers found that both vascular ultrasound and CT-derived measures of subclinical atherosclerosis can predict all-cause mortality. In a JACC study of 5.7k adults, ultrasound-based carotid plaque burden and CT-based CAC scores accurately predicted all-cause mortality over a 12-year median follow-up (HRs=1.23 & 1.15). While both imaging tools were predictive, study authors gave the edge to ultrasound thanks to its higher hazard ratios and noninvasiveness.
- Pi-Cardia’s TAVR Leaflet Clearance: Pi-Cardia announced the FDA clearance of its ShortCut leaflet modifier, which facilitates valve-in-valve TAVR procedures before implantation of a second valve. The ShortCut is the first-ever dedicated leaflet modification device, and might have a strong future, as rising TAVR volumes in patients under 65 drive a cascade of valve-in-valve procedures. Some researchers predict that over 42k valve-in-valve procedures will occur annually in the U.S. by 2035, representing ~15% of all TAVR procedures.
- Aficamten Adds oHCM Evidence: Additional analysis of Cytokinetics’ SEQUOIA-HCM Phase 3 trial added more support for aficamten’s potential to treat symptomatic obstructive HCM. Over 24 weeks, patients on aficamten showed significant improvements versus placebo in complete hemodynamic response (68% vs. 7%) and exercise capacity (47% vs. 24%), as well as a NT-proBNP decrease of ≥50% (84% vs. 8%). These findings add to the SEQUOIA-HCM trial’s solid initial results, and further bolster aficamten’s trajectory toward FDA approval.
- Stamford Adopts Bunkerhill CAC AI: Bunkerhill Health is bringing AI-powered CAC screening into Connecticut, signing a deal with Stamford Health’s Heart & Vascular Institute. The Bunkerhill CAC solution uses AI to automatically calculate CAC scores from all non-gated chest CTs, such as lung cancer screening exams. When a Stamford patient with elevated CAC is identified, their PCP or cardiologist is promptly notified with a report featuring the patient’s CAC score and MESA risk percentile, allowing early CVD detection and management.
- CHD Exam Disparities: Pregnant women with public insurance (mostly Medicaid) who gave birth to babies with congenital heart defects were far less likely to receive prenatal ultrasound screenings than women with private insurance. A study in Prenatal Diagnosis analyzed outcomes from 496 pregnant women (43% publicly insured, 62% had a baby with CHD), finding that women with public insurance were 13.2% less likely to receive a second-trimester ultrasound and 12.6% less likely to have a prenatal diagnosis
- Updated Merge Hemo Cleared: Merge by Merative received FDA clearance for an updated version of its Merge Hemo solution. Merge Hemo automates cath lab documentation into a digital patient record, while the updated version includes both new hardware and software that reduces the solution’s physical size and enhances its data visualization capabilities.
- Sub-Par HFrEF Care: It’s well known that most HF patients aren’t getting optimal GDMT, and a new survey suggests that this is largely because most physicians believe that their patients were already clinically stable and didn’t need a full HF treatment regimen. In the study of 86 physicians and 323 patients, 85.4% of HF patients weren’t prescribed quadruple therapy (ACE inhibitor/ARB/ARNI/beta blocker with MRA or SGLT2 inhibitor).
- Elucid’s Plaque Clearance: Elucid took a big strategic step, announcing the FDA clearance and limited commercial launch of its PlaqueIQ image analysis software. PlaqueIQ uses Elucid’s unique histology-based AI approach to analyze CCTA exams, creating interactive reports that quantify and classify plaque morphology. The solution enters a young-but-growing plaque AI arena that also includes solutions from Cleerly and HeartFlow. PlaqueIQ is Elucid’s first commercialized solution, while the company is also working to add a PlaqueIQ-based indication for FFRCT measurements.
- Vutrisian’s New ATTR-CM Data: New echocardiographic and biomarker data from the HELIOS-B study further supports vutrisiran’s potential as a next-gen ATTR-CM treatment. Over 30 months, vutrisiran slowed disease progression across multiple cardiac structures, including a mean left ventricular wall thickness decrease of -0.04 cm and improvements to diastolic and systolic function. This extended analysis adds to vutrisiran’s solid initial HELIOS-B data, and further supports Alnylam’s goal to complete multiple global regulatory submissions before the end of 2024.
- GE’s New Cardiac PET Tracer: Cardiac imagers will soon have another tool in their arsenal, following the FDA approval of GE HealthCare’s Flyrcado (flurpiridaz F-18) radiopharmaceutical for PET myocardial perfusion imaging. Flyrcado is indicated for patients with known or suspected coronary artery disease, and is highlighted by its long half life of 109 minutes (10x existing cardiac PET tracers) and better diagnostic accuracy compared to SPECT MPI. GE licensed the rights to flurpiridaz from Lantheus in 2017.
|
|
Incidental CAC Predicts Long-Term Risks
What if you could identify which of your asymptomatic patients have high risks of future cardiac events? Stanford-led researchers used Bunkerhill Health’s Incidental CAC algorithm to do just that, finding that patients with ≥100 incidental CAC scores had a 24% 10-year risk of developing ASCVD and far higher risks of major adverse events.
|
|
How UCSD Improved Post-Stroke Care
Viz Connect improves the monitoring of stroke patients with suspected AFib without adding layers of complexity to the clinical workflow. Hear from Brett C. Meyer, MD, on the impact it has had on post-acute stroke patient care at UCSD.
|
|
Welcome to the New Change Healthcare Cardiology
Explore Change Healthcare Cardiology’s web-enabled cardiovascular imaging platform that lets you access patient records anytime from anywhere, and brings better security, industry-leading structured reporting, and easy EMR integration.
|
|
- Streamlining Cath Lab Hemodynamic Workflows: Is your hemodynamic solution keeping your cath lab efficient? Merge Hemo is a cath lab hemodynamic monitoring solution, providing a Best in KLAS user experience, while enhancing clinical workflows, automating data collection, and streamlining inventory management.
- Experience the future of learning: Medtronic Academy 2.0 is here! Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
- Connecting the Dots in the Care Pathway: Streamline your path to patient care with this GE HealthCare Cardiology Coffee Break (Wednesday, October 16 at 12:00 PM EDT), exploring how integrated enterprise imaging solutions can empower healthcare organizations to provide precision care, achieve operational efficiency, and enhance patient satisfaction.
- Identify and Treat Cardiovascular Disease: Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
- Digital Tools for Heart Failure: Clinicians have a growing array of digital tools for assessing patients with suspected heart failure, but many don’t know what’s available. Check out this review article in Lancet Digital Health detailing the expanding list of digital HF options, including echo AI tools like those from Us2.ai.
- Accurately Measuring Heart Rate Variability: Heart rate variability measurement and analysis involves two critical elements – the ability to accurately discern the R wave in noisy environments, and using the correct analysis method for a given application. Check out how Monebo’s Kinetic HRV ECG Algorithm excels at both of these essential tasks.
- The All in One Cardiac Imaging Solution: Ready for an all-in-one solution that supports all of your MR and CT needs? See how Circle Cardiovascular Imaging’s cvi42 can streamline your core reading and reporting workflows within a single, customizable platform.
- Advance Your Cardiac MR Visualization: Ready to advance your CMRI assessments? See how you could leverage TeraRecon’s Intuition Cardiac MR package for a range of cardiac anatomy and physiology evaluations, and how your peers are already benefiting from it.
|
|
|
|
|
